@PulmCrit I think nicardipine also has the advantage of pulmonary vasodilation (over nicardipine or clevedipine). Maybe nicardipine/clevedipine over nitroprusside if you know they have unrevascularized territory and are worried about coronary steal?
@NickJohnsonMD I think that’s a great statement by you and the authors. I was not able to watch the presentation but did not initially see a similar statement in their JAMA article. I was a little worried by the large effect on ROSC and the “trend” of harm. I look forward to the larger trial.
@EdwardP60483089@MKIttlesonMD I completely admit that my lipidology game is weak. I think we don’t have medical therapies that increase HDL AND improve hard outcomes but I was under the assumption that the higher your HDL (genetics/diet/exercise) the more likely to avoid CVD and sequela?
@kaptinMD@MKIttlesonMD So true. But with the prior information that she could be a premenopausal woman and clinical trials are designed to enrich for events, I’d guess the NNT people similar to her is a higher than 92?
@AvrahamCooperMD Thank you for posting this. But I think there is also a bit of literature on the use of IV furosemide causing acute vasoconstriction (https://t.co/2v7Xe0PT0n). When I worked as a paramedic we used a lot of IV nitroglycerin. It was fast acting and more titratable.
@DSpeerbrecher@Toaster_Pastry I think he referring to the chronic management of patients with CHF as opposed to the acute treatment we see when patients call 911 with acute SOB.